Rigel Pharmaceuticals, Inc. (RIGL)
49.42
+1.92
(+4.04%)
USD |
NASDAQ |
Sep 02, 16:00
49.46
+0.04
(+0.08%)
After-Hours: 20:00
Rigel Pharmaceuticals Research and Development Expense (TTM) : 43.68M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 43.68M |
| March 31, 2026 | 36.54M |
| December 31, 2025 | 33.30M |
| September 30, 2025 | 28.24M |
| June 30, 2025 | 27.07M |
| March 31, 2025 | 25.79M |
| December 31, 2024 | 23.38M |
| September 30, 2024 | 20.93M |
| June 30, 2024 | 21.23M |
| March 31, 2024 | 20.46M |
| December 31, 2023 | 24.52M |
| September 30, 2023 | 36.70M |
| June 30, 2023 | 44.89M |
| March 31, 2023 | 54.89M |
| December 31, 2022 | 60.27M |
| September 30, 2022 | 58.21M |
| June 30, 2022 | 61.84M |
| March 31, 2022 | 63.88M |
| December 31, 2021 | 65.24M |
| September 30, 2021 | 67.07M |
| June 30, 2021 | 63.37M |
| March 31, 2021 | 60.78M |
| December 31, 2020 | 60.10M |
| September 30, 2020 | 59.21M |
| June 30, 2020 | 59.07M |
| Date | Value |
|---|---|
| March 31, 2020 | 58.08M |
| December 31, 2019 | 52.88M |
| September 30, 2019 | 52.40M |
| June 30, 2019 | 49.04M |
| March 31, 2019 | 46.61M |
| December 31, 2018 | 46.90M |
| September 30, 2018 | 44.70M |
| June 30, 2018 | 44.41M |
| March 31, 2018 | 45.14M |
| December 31, 2017 | 46.27M |
| September 30, 2017 | 46.34M |
| June 30, 2017 | 51.70M |
| March 31, 2017 | 57.65M |
| December 31, 2016 | 63.45M |
| September 30, 2016 | 68.38M |
| June 30, 2016 | 67.70M |
| March 31, 2016 | 65.30M |
| December 31, 2015 | 62.82M |
| September 30, 2015 | 60.88M |
| June 30, 2015 | 61.52M |
| March 31, 2015 | 66.53M |
| December 31, 2014 | 67.70M |
| September 30, 2014 | 71.13M |
| June 30, 2014 | 72.55M |
| March 31, 2014 | 71.88M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Ironwood Pharmaceuticals, Inc. | 86.86M |
| Cytokinetics, Inc. | 384.41M |
| Perspective Therapeutics, Inc. | 82.13M |
| Capricor Therapeutics, Inc. | 98.66M |
| ACADIA Pharmaceuticals, Inc. | 331.01M |